

---

## WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

MAY 2, 2017

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target. Under the terms of the agreement, Agios will conduct pre-clinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

The WilmerHale team counseling Agios Pharmaceuticals included [Steven Barrett](#) and [Mat Trachok](#).

Read Agios Pharmaceuticals' [press release](#) for more information.